Principles and Challenges in anti-COVID-19 Vaccine Development

The number of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-infected patients keeps rising in most of the European countries despite the pandemic precaution measures. The current antiviral and anti-inflammatory therapeutic approaches are only supportive, have limited efficacy, and the prevention in reducing the transmission of SARS-CoV-2 virus is the best hope for public health. It is presumed that an effective vaccination against SARS-CoV-2 infection could mobilize the innate and adaptive immune responses and provide a protection against severe forms of coronavirus disease 2019 (COVID-19) disease. As the race for the effective and safe vaccine has begun, different strategies were introduced. To date, viral vector-based vaccines, genetic vaccines, attenuated vaccines, and protein-based vaccines are the major vaccine types tested in the clinical trials. Over 80 clinical trials have been initiated; however, only 18 vaccines have reached the clinical phase II/III or III, and 4 vaccine candidates are under consideration or have been approved for the use so far. In addition, the protective effect of the off-target vaccines, such asBacillus Calmette-Gu érin and measles vaccine, is being explored in randomized prospective clinical trials with SARS-CoV-2-infected patients. In this review, we discuss the most promising anti-COVID-19 vaccine clinical trials and different vaccination strategies in order to provide more clarity into the ongoing clinica l trials.Int ...
Source: International Archives of Allergy and Immunology - Category: Allergy & Immunology Source Type: research

Related Links:

Dysfunctional breathing, hypocapnia, and myalgic encephalomyelitis/chronic fatigue syndrome were seen in symptomatic patients post-acute COVID-19 despite normal chest imaging and pulmonary function.Medscape Medical News
Source: Medscape Cardiology Headlines - Category: Cardiology Tags: Cardiology News Source Type: news
Two days after the first case of the new Omicron Covid-19 variant was officially confirmed in Massachusetts, the head of the state's largest hospital system stressed the importance of vaccines and masks.
Source: Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news
Two years into the pandemic, what's next?
Source: Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news
Prioritizing workforce well-being is a key driver of business success. The COVID-19 pandemic changed the world more than any event in recent history, significantly impacting the health and well-being of our workforce and economy. The inextricable link between individual health and productivity, business performance and economic prosperity is clear, and now is the time for employers to actively engage and support the mental and physical health of employees. In a recent survey by The Economist Intelligence…
Source: Health Care News Headlines - Category: Health Management Authors: Source Type: news
Dr F Perry Wilson reviews new data about post-mRNA vaccine myocarditis: who is affected, severity, treatment, and outcomes.Medscape
Source: Medscape Internal Medicine Headlines - Category: Internal Medicine Tags: Internal Medicine Commentary Source Type: news
' Thus far, it does not look like there's a great degree of severity to it,'Anthony Fauci, MD, director of the National Institute of Allergy and Infectious Diseases, told CNN's State of the Union.WebMD Health News
Source: Medscape Med Students Headlines - Category: Universities & Medical Training Tags: Infectious Diseases News Source Type: news
When does a pandemic end? Is it when life regains a semblance of normality? Is it when the world reaches herd immunity, the benchmark at which enough people are immune to an infectious disease to stop its widespread circulation? Or is it when the disease is defeated, the last patient cured and the pathogen retired to the history books? The last scenario, in the case of COVID-19, is likely a ways off, if it ever arrives. The virus has infected more than 100 million people worldwide and killed more than 2 million. New viral variants even more contagious than those that started the pandemic are spreading across the world. And...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized Cover Story COVID-19 feature Magazine Source Type: news
“No!” The doctor snapped. “Look at me!” I had been staring her in the eyes, as she had ordered, but when a doctor on my other side began jabbing me with a needle, I started to turn my head. “Don’t look at it,” the first doctor said. I obeyed. This was in early August in New Orleans, where I had signed up to be a participant in the clinical trial for the Pfizer-BioNTech COVID-19 vaccine. It was a blind study, which meant I was not supposed to know whether I had gotten the placebo or the real vaccine. I asked the doctor if I would really been able to tell by looking at the syringe. &...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized COVID-19 feature Magazine Source Type: news
It’s wasn’t a typical Sunday morning for Dr. Stephen Hoge, president of the biotech company Moderna, and Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases. They were at their respective homes in Massachusetts and Washington, D.C., waiting to to be let into a Zoom call to hear the results of the very first COVID-19 vaccine that was tested in people. The hosts were members of the independent Data Safety Monitoring Board (DSMB) that is reviewing data involving all the COVID-19 vaccine candidates supported by the U.S. government’s Operation Warp Speed program, and Hoge a...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized COVID-19 Source Type: news
In early April, about four months after a new, highly infectious coronavirus was first identified in China, an international group of scientists reported encouraging results from a study of an experimental drug for treating the viral disease known as COVID-19. It was a small study, reported in the New England Journal of Medicine, but showed that remdesivir, an unapproved drug that was originally developed to fight Ebola, helped 68% of patients with severe breathing problems due to COVID-19 to improve; 60% of those who relied on a ventilator to breathe and took the drug were able to wean themselves off the machines after 18...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized COVID-19 Source Type: news
More News: Allergy | Allergy & Immunology | Clinical Trials | Coronavirus | COVID-19 | Genetics | Information Technology | International Medicine & Public Health | Measles | Measles Vaccine | Pandemics | Respiratory Medicine | SARS | Vaccines